Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK

Femme et Homme Max 99 ans
MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK MAJ Il y a 4 ans

A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy The primary objective of this study is to evaluate the efficacy of MEDI2070 versus placebo to induce clinical remission based on the CDAI score at Week 8 in subjects with moderate to severe CD who hav...

Pays Aucun
Organes Aucun
Spécialités Aucune

unknown

Plus d'informations